Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VRDN vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRDN Captures Overall Composite Edge (36.8 SELL vs 35.5 SELL), While MESO Leads 3–2 on Growth & Valuation Pillars

VRDN Overall Winner 6-Pillar Tally: VRDN 2 – 3 MESO (1 Tie) Matrix Metrics: VRDN 7 – 3 MESO

As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (36.8/100 SELL vs. 35.5/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. VRDN trades at $30.22 (1.0x Forward P/E, -1781.4% operating margin) versus MESO at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Growth vs. Quality Trade-Off: VRDN earns the overall head-to-head edge with a stronger Unified Composite Score (36.8/100 SELL vs. MESO 35.5/100 SELL) and 1.12β · 64% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although VRDN compares more favorably head-to-head, both VRDN (36.8/100 SELL) and MESO (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRDN vs MESO
VRDN NASDAQ Head-to-Head Winner
Viridian Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$30.22
-2.1% 1D
Market Cap $3.5B
TTM Revenue $26M
Forward P/E 1.0x
Beta / 30D Vol 1.12β · 64% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 72
RSI-14: 72.2 · SMA20: $26.61 · SMA50: $22.89
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (VRDN 2 – 3 MESO)

Columns: Metric · VRDN · MESO
1. Valuation Multiples VRDN
Forward P/E 1.0x N/M
Trailing P/E 1.0x N/M
PEG Ratio N/M N/M
EV / Revenue 134.2x 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) -63.5% +390.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $26M $120M
Market Cap $3.5B $1.7B
3. Profitability & Quality MESO
Gross Margin N/A 80.0%
Operating Margin -1781.4% -42.6%
Net Profit Margin 0.0% -47.8%
Return on Equity (ROE) -83.7% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$353M -$45M EBITDA
Cash Flow Margin N/A -37.1% EBITDA Mgn
Net Cash / Leverage $70M Net Debt (0.42x D/E) $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VRDN
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 87.7% (20th %ile) 76.8% (37th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRDN (7) vs MESO (3)
Institutional Metric VRDN MESO Criterion Row Edge
Market Capitalization
Scale
$3.5B $1.7B Larger Scale VRDN
Trailing P/E Ratio
Valuation
1.0x N/M Lower Multiple VRDN
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple VRDN
Revenue Growth (YoY)
Growth
-63.5% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
-1781.4% -42.6% Higher Margin MESO
Net Profit Margin
Profitability
0.0% -47.8% Higher Margin VRDN
Return on Equity (ROE)
Capital Efficiency
-83.7% -9.9% Higher ROE MESO
52-Week Range Position
Momentum
81% ($13–$34) 6% ($12–$22) Stronger Trend VRDN
Beta / 30D Volatility
Risk Regime
1.12β · 64% Vol 1.18β · 78% Vol Lower Realized Risk VRDN
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 35.5 / 100 (SELL) Higher Composite VRDN
Trailing 12M Revenue (USD)
Operating Scale
$26M $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 134.2x EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$353M ($70M Net Debt (0.42x D/E)) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VRDN +64.92 pp
VRDN: +58.82% · MESO: -6.1%
3M Horizon VRDN +51.49 pp
VRDN: +26.3% · MESO: -25.19%
6M Horizon VRDN +102.54 pp
VRDN: +87.72% · MESO: -14.82%
1Y Horizon VRDN +22.5 pp
VRDN: +6.08% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRDN vs MESO. Trailing 12-month operating profitability (VRDN -1781.4% vs MESO -42.6%) and valuation multiples (VRDN 1.0x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VRDN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$26M
Gross MarginN/A
Op. Margin-1781.4%
ROE / Fwd P/E-83.7% · 1.0x
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRDN SURGE
5d in phase · OBV ACCUMULATION
Current IV 87.7%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact VRDN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRDN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and -1781.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VRDN vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (36.8/100 SELL vs. 35.5/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. VRDN trades at $30.22 (1.0x Forward P/E, -1781.4% operating margin) versus MESO at $12.47 (N/M Forward P/E, -42.6% operating margin). Growth vs. Quality Trade-Off: VRDN earns the overall head-to-head edge with a stronger Unified Composite Score (36.8/100 SELL vs. MESO 35.5/100 SELL) and 1.12β · 64% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although VRDN compares more favorably head-to-head, both VRDN (36.8/100 SELL) and MESO (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: VRDN posts -63.5% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (N/A gross margin, -1781.4% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, VRDN generates $26M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, VRDN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

VRDN screens cheaper on headline valuation multiples. VRDN trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and 134.2x EV/Revenue (unreported FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRDN (-83.7% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, VRDN carries 87.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.12β · 64% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.